Correlation of PIM kinases with tumor immune microenvironment and clinical presentation of metastatic hormone-sensitive prostate cancer.

被引：0
|
作者：
Recio-Boiles, Alejandro
Clements, Amber N.
Deshmukh, Sachin Kumar
Bertolo, Aaron
Estrada-Mendizabal, Ricardo J.
Saboda, Kathylynn
Wu, Sharon
Xiu, Joanne
Radovich, Milan
Sutterby, Kai
Chauhan, Shailender S.
McKay, Rana R.
Nabhan, Chadi
Warfel, Noel A.
机构：
[1] Univ Arizona, Canc Ctr, Tucson, AZ USA
[2] Caris Life Sci, Phoenix, AZ USA
[3] Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey, Mexico
[4] Univ Calif San Diego, La Jolla, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.211
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
211
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [1] PIM kinases alter the prostate tumor immune microenvironment
    Clements, Amber N.
    Sutterby, Kai
    Deshmukh, Sachin Kumar
    Wu, Sharon
    Xiu, Joanne
    Farrell, Alex
    Radovich, Milan
    Nabhan, Chadi
    Heath, Elisabeth I.
    McKay, Rana R.
    Recio-Boiles, Alejandro
    Warfel, Noel A.
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer
    Yamada, Yasutaka
    Sakamoto, Shinichi
    Tsujino, Takuya
    Saito, Sinpei
    Sato, Kodai
    Nishimura, Kazuki
    Fukushima, Tatsuo
    Nakamura, Ko
    Yoshikawa, Yuki
    Matsunaga, Tomohisa
    Maenosono, Ryoichi
    Kanesaka, Manato
    Arai, Takayuki
    Sazuka, Tomokazu
    Imamura, Yusuke
    Komura, Kazumasa
    Mikami, Kazuo
    Nakamura, Kazuyoshi
    Fukasawa, Satoshi
    Chiba, Kazuto
    Naya, Yukio
    Nagata, Maki
    Komaru, Atsushi
    Nakatsu, Hiroomi
    Azuma, Haruhito
    Ichikawa, Tomohiko
    PROSTATE INTERNATIONAL, 2025, 13 (01) : 60 - 66
  • [3] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
  • [4] Survival and comorbid diabetes mellitus in metastatic hormone-sensitive prostate cancer.
    Baxi, Priya
    Eaton, Daniel B.
    Puri, Varun
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 74 - 74
  • [5] Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.
    Bukhari, Nedal
    Potvin, Kvica R.
    Ernst, D. Scott
    Sax, Lori
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Cardiovascular medications and overall survival in metastatic hormone-sensitive prostate cancer.
    Pickett, Carley
    Eaton, Daniel B.
    Tohmasi, Steven
    Karunanandaa, Krishny
    Gopukumar, Deepika
    Puri, Varun
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 75 - 75
  • [7] Management of Metastatic Hormone-Sensitive Prostate Cancer
    Bernard, Brandon
    Sweeney, Christopher J.
    CURRENT UROLOGY REPORTS, 2015, 16 (03)
  • [8] Rezvilutamide for metastatic hormone-sensitive prostate cancer
    Singh, Kirti
    Mandal, Swarnendu
    Nayak, Prasant
    Das, Manoj
    Tripathy, Sambit
    LANCET ONCOLOGY, 2022, 23 (11): : E490 - E490
  • [9] Treatment of metastatic hormone-sensitive prostate cancer
    Rane, Jayant K.
    Chowdhury, Amani
    Kinnaird, William
    Marks, Gillian
    Davda, Reena
    TRENDS IN UROLOGY & MENS HEALTH, 2021, 12 (06) : 7 - 10
  • [10] Docetaxel for hormone-sensitive metastatic prostate cancer
    Baker, Holly
    LANCET ONCOLOGY, 2015, 16 (09): : E432 - E432
12345